ELTP — ELITE PHARMACEUTICALS INC /NV/

—
OTC · Health Care · Pharmaceuticals · CIK 1053369 ·
Last close
$0.37
Market Cap
$397.36M
52W High
$0.60
52W Low
$0.21
ADV30
735,043
Next earnings
2026-11-12
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 40,081,960 15,987,295 9,925,451 17,318,746 144,287,718 34,862,578 22,122,609
Jun 2026 32,355,283 13,507,545 7,529,281 5,910,565 139,669,132 38,940,138 34,843,076
Mar 2026 40,748,067 20,772,157 11,033,800 18,461,188 138,289,840 29,797,800 39,406,865
Dec 2025 31,589,251 12,953,175 9,012,943 18,593,806 126,412,637 21,094,904 46,098,554

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$19,042,069
Investing CF
$-1,516,386
Financing CF
$-306,219
CapEx
$-1,516,386
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.02
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-69,920,675
Inventory
$24,200,388
Receivables
$50,441,624
ST Investments
—
EBIT TTM
$65,406,081
Pretax Income TTM
$65,095,240
Interest Exp TTM
$310,841
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$141,014,304
EBITDA
$37,310,520
Free Cash Flow
$23,001,620
Enterprise Value
$249,919,312
Total Cash
$38,940,136
Total Debt
$5,572,569
Shares Out
1,077,136,442
Trailing EPS
$0.04
Book Value
$0.10
ROE
74.3%
ROA
17.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 148,870,119 49,960,196 44,872,686 138,289,840 39,406,865 98,882,975 23,748,094
Mar 2025 84,043,929 21,203,894 -4,314,659 96,387,477 42,872,448 53,515,029 7,455,639
Mar 2024 56,625,128 10,788,769 20,108,631 83,653,536 26,070,718 57,582,818 -3,235,115
Mar 2023 34,155,114 3,968,809 3,561,846 40,896,018 11,935,758 28,960,260 3,338,704

TTM Snapshot

Revenues TTM
$141,014,305
NetIncome TTM
$56,667,966
OpCashFlow TTM
—
Assets (Latest)
$139,669,132
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
IRD Opus Genetics, Inc. $391.45M $4.05 —
PTCHF PureTech Health plc $405.77M $1.65 —
RZLT Rezolute, Inc. $388.37M $4.01 —
AVTX Avalo Therapeutics, Inc. $412.28M $7.13 —
OCS Oculis Holding AG $417.01M $7.51 —

News headlines (Yahoo Finance, 1h cache)

What Elite Pharmaceuticals (ELTP) Said on Its Q2 Earnings Call
2026-11-13 20:14 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information
2026-11-12 21:38 · Yahoo
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter of Fiscal Year 2027 Financial Results on November 13, 2026
2026-11-10 19:54 · Yahoo
Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq.
2026-11-03 12:30 · Yahoo
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
2026-10-07 15:08 · Yahoo
ELTP Downgraded to Neutral on Pricing Pressure & Limited Visibility
2026-09-10 16:53 · Yahoo
Elite Pharmaceuticals Inc (ELTP) (Q1 2027) Earnings Call Highlights: Steady Revenue and ...
2026-08-18 01:08 · Yahoo
Elite Pharmaceuticals Q1 Earnings Call Highlights
2026-08-14 19:02 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
2026-08-13 20:11 · Yahoo
Elite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call Highlights: Record Revenue Growth and ...
2026-07-01 01:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.